Esperion to Report Third Quarter 2025 Financial Results on November 6

Rhea-AI Summary

Esperion (NASDAQ: ESPR) will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025.

Management will host a live webcast at 8:00 a.m. ET to discuss results and business updates; a replay will be available about two hours after the call and archived on the company website for ~90 days.

Esperion is a commercial-stage biopharmaceutical company marketing the only FDA-approved oral, once-daily non-statin therapies for patients with elevated LDL-C, supported by the ~14,000-patient CLEAR cardiovascular outcomes trial. The company is advancing next-generation ATP citrate lyase inhibitor (ACLYi) programs and pursuing international partnerships and commercial expansion.

News Market Reaction

-1.47%

1 alert

-1.47% News Effect

On the day this news was published, ESPR declined 1.47%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

ANN ARBOR, Mich., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025.

Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates.

A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.

Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.

Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.

Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903

Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438

FAQ

When will Esperion (ESPR) report Q3 2025 results?

Esperion will report Q3 2025 results before the market opens on November 6, 2025.

What time is the Esperion (ESPR) Q3 2025 earnings webcast?

Management will host a live webcast at 8:00 a.m. ET on November 6, 2025.

Where can investors access the Esperion (ESPR) webcast and replay?

The live audio webcast is on Esperion's investor site; replay is posted about two hours after the call and archived for ~90 days.

What commercial products does Esperion (ESPR) market?

Esperion markets the only FDA-approved oral, once-daily non-statin medicines for patients with elevated LDL-C.

What clinical evidence supports Esperion's (ESPR) marketed therapies?

The marketed medicines are supported by the ~14,000-patient CLEAR cardiovascular outcomes trial.

What R&D program is Esperion (ESPR) advancing beyond its marketed products?

Esperion is advancing next-generation ATP citrate lyase inhibitor (ACLYi) programs focused on potent, specific allosteric inhibitors.